In a reversal of Trump administration policy, the U.S. Food and Drug administration will soon require premarket review of laboratory-developed tests for COVID-19 and other diseases, throwing test makers into a position of regulatory uncertainty that will likely be resolved through litigation or legislation, say Stacy Amin and Bethany Hills at MoFo.